跳至主要内容
临床试验/CTRI/2018/09/015676
CTRI/2018/09/015676已完成未知

Effect of Domperidone, 5-HT3 Antagonist and Olanzapine Containing Antiemetic Regimen on QT interval in Patients with Malignancy

Dr Ashwin Kamath0 个研究点目标入组 36 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Will be receiving domperidone, 5-HT3 antagonist and olanzapine containing antiemetic regimen
  • 2. ECOG status <= 2
  • 3. Willing to provide informed consent

排除标准

  • 1. Baseline QTc interval > 450 milliseconds
  • 2. History of cardiac arrhythmias
  • 3. A history of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)
  • 4. The use of concomitant medications that prolong the QT/QTc (other than the study drugs)
  • 5. If the investigator is of the opinion that the patient will be unable to complete the study due to any reasons

研究者

发起方
Dr Ashwin Kamath

相似试验